Back to News
Market Impact: 0.3
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Source: GlobeNewswire
Healthcare & BiotechRegulation & LegislationProduct Launches
Prime Medicine announced regulatory clearance for PM577a, advancing execution across its liver-focused franchise and adding to recent clearances for related programs. The clearance supports the company’s modular prime-editing platform, although the key clinical catalyst remains distant, with initial data not expected until 2027.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
PRME0.62
More News
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- UniCredit CEO Plots Commerzbank Governance Overhaul
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion